Cholinergic urticaria (CholU), a subtype of chronic inducible urticaria (CIndU), is characterized by pinpoint, highly pruritic wheals with surrounding erythema caused by increased core body temperature.1 CIndU does not respond well to H1-antihistamines (H1AH).2,3 Omalizumab, a monoclonal antibody against immunoglobulin E, is a new therapeutic option for not only recalcitrant chronic spontaneous urticaria (CSU) but also various types of CIndU, including dermographism and cold urticaria.2-4 Omalizumab treatment for CholU has been reported mostly in Western countries.3,4 Here, we retrospectively analyzed omalizumab efficacy and its association with clinical characteristics in 27 H1AH-refractory CholU patients in Korea.
展开▼
